Drospifem 30 (ethinylestradiol, drospirenone) coated tablets 0.03 mg/3 mg. №21


Manufacturer: Ukraine



Oral contraception. The decision to prescribe Drospifem 20 should be made taking into account the individual risk factors of the patient, in particular the risk factors for venous thromboembolism (VTE). You should also compare the risk of VTE during the treatment of Drospifem 20 with such a risk during treatment with other combined hormonal contraceptives (KGC) (see the sections “Contraindications” and “Features of use”).